finance.yahoo.com (nprofile…mr8r)
https://s.yimg.com/ny/api/res/1.2/W2IgyITSOXNnFeA265JwxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/0a886363d77cee337ab330e5d82d25cb
https://finance.yahoo.com/news/why-iovance-biotherapeutics-tumbled-nearly-223909778.html
finance.yahoo.com / Yahoo! Finance
npub1va…rwc3n
2025-05-18 05:54:25
Author Public Key
npub1vap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aessgrwc3nPublished at
2025-05-18 05:54:25Event JSON
{
"id": "0b4d41ac5d2c13230e76bc211668f452fe6350f27317940a794aa54b131c1b25",
"pubkey": "6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"created_at": 1747547665,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/why-iovance-biotherapeutics-tumbled-nearly-223909778.html"
],
[
"subject",
"Why Iovance Biotherapeutics Tumbled by Nearly 6% Today"
],
[
"published_at",
"1747435149"
],
[
"image",
"https://s.yimg.com/ny/api/res/1.2/W2IgyITSOXNnFeA265JwxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/0a886363d77cee337ab330e5d82d25cb"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://s.yimg.com/ny/api/res/1.2/W2IgyITSOXNnFeA265JwxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/0a886363d77cee337ab330e5d82d25cb"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"The analyst, David Dai of UBS, lowered his price target to $2 per share from $17, citing below-expectation sales of the company's advanced melanoma drug Amtagvi and higher drop-out rates for the drug. Dai expressed concern about the slow ramp-up of the company's commercialization and flaws in patient selection. The company's revenue guidance cut in the earnings report also raised concerns."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqvap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aesst3mr8r\nhttps://s.yimg.com/ny/api/res/1.2/W2IgyITSOXNnFeA265JwxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/0a886363d77cee337ab330e5d82d25cb\n\nhttps://finance.yahoo.com/news/why-iovance-biotherapeutics-tumbled-nearly-223909778.html",
"sig": "ca62d272653d9f3b0a207074f47e130ebe5c95254415ce5806602344bfff0d22a19dcda01d88ca67db40ee1c2424439150df72fd1d977e776524a41e1fe60e43"
}